Kratom is the plant and the products made from its leaves, while 7-hydroxymitragynine (7-OH) is one specific compound found naturally in kratom in trace amounts. They are not two competing products; 7-OH is one of the many alkaloids associated with the kratom plant.
The confusion comes from newer products marketed specifically as “7-OH.” These products can contain much higher 7-OH concentrations than naturally occur in traditional kratom leaf, which is why regulators distinguish concentrated or semisynthetic 7-OH products from traditional botanical kratom.
This post explains the differences between kratom and 7-hydroxymitragynine, what research shows about their effects and risks, and why concentrated 7-OH products are receiving increased regulatory attention.
What Is Kratom? The Leaf, Its Alkaloids, and Common Kratom Products
Kratom comes from Mitragyna speciosa, a tropical tree native to Southeast Asia. According to the DEA fact sheet, kratom leaves have traditionally been chewed or prepared as tea, while products sold in the United States include dried or powdered leaf, capsules, teas, and extracts.
Kratom extract contains numerous alkaloids, with mitragynine as the dominant one and 7-OH occurring naturally at much lower levels.
These compounds interact with opioid receptors, although their pharmacological effects are not identical. Research into kratom’s effects and long-term safety remains limited.
The FDA has not approved kratom or its known alkaloids for any medical use. The agency also states that kratom is not lawfully marketed in the United States as a drug, dietary supplement, or food additive.
What Is 7-Hydroxymitragynine (7-OH)?
7-hydroxymitragynine, or 7-OH, is an alkaloid naturally present in kratom leaves in trace amounts. The body can also produce it when it metabolizes mitragynine. A 2026 analysis describes 7-OH as both a minor natural alkaloid in kratom and an active metabolite of mitragynine.
7-OH acts at the mu-opioid receptor and is substantially more active than mitragynine. This difference in pharmacology becomes particularly important when products contain higher concentrations of 7-OH rather than the trace amounts naturally found in kratom leaf.
Kratom vs 7-OH: Key Differences in Composition, Potency, and Risk
Kratom and 7-hydroxymitragynine (7-OH) are related but are not the same thing.
Kratom refers to the leaves of Mitragyna speciosa, which contain multiple naturally occurring alkaloids. 7-OH is one of those alkaloids and occurs naturally in kratom in much smaller amounts than mitragynine.
| Feature | Kratom | 7-OH |
| What it is | Leaves or products derived from Mitragyna speciosa | A naturally occurring alkaloid found in kratom |
| Primary alkaloid | Mitragynine is the most abundant major alkaloid | 7-hydroxymitragynine |
| Natural presence | Contains multiple alkaloids, including small amounts of 7-OH | Naturally present in kratom at relatively low levels |
| Pharmacology | Effects reflect the activity of multiple kratom alkaloids | Has activity at mu-opioid receptors and is more potent than mitragynine at these receptors |
| Common forms | Leaf, powder, tea, capsules, and extracts | May be present naturally in kratom or isolated as a distinct substance |
| Risk considerations | Can be associated with adverse effects, dependence, and withdrawal | Its greater mu-opioid receptor activity raises concerns about dependence, withdrawal, and other opioid-like effects |
| Regulatory focus | Regulation varies by state and jurisdiction | Increasingly subject to specific regulatory attention |
The key distinction is that kratom is a botanical substance containing a mixture of naturally occurring compounds, while 7-OH is a specific alkaloid found within that plant.
Naturally occurring 7-OH is therefore not synonymous with kratom itself, and the presence of 7-OH does not mean that a kratom product is a 7-OH product.
Kratom Leaf vs Concentrated 7-OH Products: Why Concentration Changes Everything
A traditional kratom product contains a mixture of naturally occurring alkaloids. A concentrated 7-OH product is designed to provide substantially more 7-OH than would normally be present in the plant.
The FDA specifically distinguishes natural kratom leaf from concentrated 7-OH products and has focused its regulatory actions on products containing concentrated or synthetic 7-OH rather than natural leaf containing only trace levels.
Product composition is another concern. A 2026 analysis of commercial products labeled as containing 7-OH found evidence of semisynthetic 7-OH in more than 98% of the products analyzed. It also identified inconsistencies between labeled and measured amounts in some products.
This means the word “kratom” on a product label does not necessarily tell you how much 7-OH the product contains or whether the 7-OH is naturally occurring or semisynthetically produced.
Why Concentrated 7-Hydroxymitragynine Products Are Drawing Regulatory Attention
Regulatory attention is increasingly focused on concentrated and semisynthetic 7-OH rather than the trace amounts naturally present in botanical kratom. 7-OH produces stronger opioid-like effects at higher concentrations, which may increase concerns about 7-OH dependence, withdrawal, and other adverse health effects.
The FDA has warned about concentrated 7-OH products and previously recommended federal scheduling action for certain 7-OH products. The agency has specifically stated that its actions target concentrated 7-OH rather than natural kratom leaf products.
The federal picture also changed in 2026. On August 26, 2026, a DEA temporary scheduling order published in the Federal Register took effect, placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I.
Separately, the DEA has initiated a temporary scheduling process for 7-OH above a specified threshold.
The HHS notice extended the public comment period on the proposed threshold through September 10, 2026. This deadline marks the end of the comment period, not a final decision on whether 7-OH above the proposed threshold will be temporarily placed in Schedule I.
Effects and Risks: What the Evidence Shows
Kratom and 7-hydroxymitragynine (7-OH) can produce different effects because kratom contains multiple alkaloids, while 7-OH is a specific alkaloid that activates mu-opioid receptors.
Kratom: Effects
Reported effects of kratom can vary depending on the amount used, product composition, and individual factors. They may include:
- Increased alertness and energy
- Increased sociability
- Relaxation
- Pain relief
- Reduced anxiety
Kratom: Risks
Kratom use has also been associated with:
- Nausea and vomiting
- Constipation
- Dizziness or drowsiness
- Increased heart rate
- Dependence and withdrawal symptoms, particularly with regular use
Research into kratom’s long-term effects and safety is still developing.
7-OH: Effects
7-OH has stronger activity at the mu-opioid receptor than mitragynine. Reported effects may include:
- Pain relief
- Relaxation
- Euphoria
- Drowsiness
7-OH: Risks
The stronger opioid-receptor activity of 7-OH raises concerns about:
- Physical dependence
- Withdrawal symptoms
- Addiction and compulsive use
- Anxiety
- Gastrointestinal symptoms
- Insomnia
- Seizures
America’s Poison Centers has also reported increasing exposure cases involving 7-OH and other kratom-derived products. Its 2026 advisory notes that concentrated 7-OH products may have stronger opioid-like effects than traditional kratom products.
Can Kratom or 7-OH Cause Dependence and Withdrawal?
Yes. Regular use of kratom or concentrated 7-OH can be associated with physical dependence and withdrawal. The FDA reports that some people who use kratom develop substance use disorder and experience withdrawal when they stop using it.
The concern may be greater with concentrated 7-OH because of its potent activity at the mu-opioid receptor. A 2026 case report documented acute withdrawal after abrupt discontinuation of chronic, high-dose concentrated 7-OH. Reported symptoms included nausea, diarrhea, abdominal cramping, restlessness, chills or clamminess, and anxiety.
If you want a more detailed explanation of kratom and 7-OH withdrawal, see what kratom and 7-OH withdrawal involves and what withdrawal management involves.
Withdrawal experiences can vary based on the substance, amount and frequency of use, duration of use, and individual factors. A healthcare professional can help assess these factors and discuss appropriate support.
When to Talk to a Healthcare Professional
Professional guidance may be appropriate if your use has escalated, attempts to stop have produced withdrawal symptoms, use continues despite negative consequences, or kratom or 7-OH is being used alongside other substances.
Stopping an opioid-receptor-active substance after regular use can be uncomfortable. A healthcare professional can assess your pattern of use, withdrawal concerns, other substances involved, and available treatment options.
If treatment is appropriate, 7-OH addiction treatment programs may be one option to discuss with a qualified provider. Calusa Recovery also offers treatment programs, including outpatient treatment options when that level of care is appropriate.
If kratom or 7-OH use is occurring alongside significant mental health concerns, a professional can also assess whether co-occurring mental health and substance use treatment is appropriate rather than assuming the substance use can be addressed separately.
Conclusion
The simplest way to understand 7-OH and kratom is that kratom is the plant, while 7-OH is one of its naturally occurring alkaloids. The major regulatory concern involves 7-OH concentrate products or otherwise increasing 7-OH far beyond the levels naturally found in kratom leaf.
That distinction matters when evaluating product composition, potential risks, dependence, and changing regulations. If regular use has become difficult to control or stopping causes withdrawal symptoms, professional support can help you understand your options.
At Calusa Recovery, we provide treatment programs for people who need support with substance use and related concerns. Start with our treatment programs today if kratom or 7-OH use has become difficult to control.
Frequently Asked Questions
Is 7-hydroxymitragynine the same as kratom?
No. Kratom refers to the Mitragyna speciosa plant and products made from its leaves. 7-OH is one alkaloid naturally found in kratom, generally at trace levels.
Is 7-OH an opioid?
7-OH is a kratom alkaloid and an opioid-receptor-active compound that acts at the mu-opioid receptor. The FDA describes concentrated 7-OH products as potent opioid products and has focused regulatory attention on these products.
Does 7-OH show up on a drug test?
Not necessarily on a standard opioid screen. Common opioid immunoassays are designed to detect particular opioid compounds and may not reliably detect kratom alkaloids such as mitragynine and 7-OH. Specialized testing may be needed to identify these compounds.
Is it safe to use 7-OH regularly?
There is not enough evidence to show that regular 7-OH use is safe. The FDA has raised concerns about concentrated 7-OH products and reports adverse effects including withdrawal, gastrointestinal symptoms, anxiety, insomnia, and seizures.
Is kratom federally legal?
Kratom and mitragynine are not currently federally controlled, but three kratom-derived substances were placed in Schedule I on August 26, 2026. A separate federal process for 7-OH above a proposed threshold is still ongoing.
Are 7-OH products the same as traditional kratom products?
No. Traditional kratom contains multiple alkaloids and only trace amounts of 7-OH, while some 7-OH products contain much higher levels of the alkaloid, including concentrated or semisynthetic forms.
